677 Results for "

available

" in MedChemExpress (MCE) Product Catalog:
Products (677)

677 Results for "available" in MCE Product Catalog:

134
134 Publications Verification
Cat. No.: HY-18072
CAS No.: 1337531-36-8
Target:  

PERK Autophagy Apoptosis

Research Areas:  

Cancer

GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC50 of 0.4 nM.
loading...
    loading...
106
106 Cited Publications
Cat. No.: HY-108413
CAS No.: 1373431-65-2
Purity:  99.95%
Synonyms: BMN 673ts
Target:  

PARP

Research Areas:  

Cancer

Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC50 of 0.57 nM for PARP1.
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-40354
CAS No.: 477600-75-2
Synonyms: Tasocitinib; CP-690550
Target:  

JAK Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
loading...
    loading...
100
100 Cited Publications
Cat. No.: HY-40354A
CAS No.: 540737-29-9
Synonyms: Tasocitinib citrate; CP-690550 citrate
Tofacitinib citrate is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.
loading...
    loading...
98
98 Cited Publications
Cat. No.: HY-13803
CAS No.: 1403254-99-8
Purity:  99.93%
Synonyms: EPZ-6438; E-7438
Research Areas:  

Cancer

Tazemetostat (EPZ-6438) is a potent, selective and orally available EZH2 inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a Ki value of 2.5 nM. Tazemetostat inhibits EZH2 with IC50s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC50 of 4 nM. Tazemetostat also inhibits EZH1 with an IC50 of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .
loading...
    loading...
76
76 Cited Publications
Cat. No.: HY-100388A
CAS No.: 2200214-93-1
Purity:  99.87%
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

SHP099 hydrochloride is a potent, selective and orally available SHP2 inhibitor with an IC50 of 70 nM .
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-130149
CAS No.: 2326521-71-3
Purity:  99.81%
Synonyms: MRTX849
Target:  

Ras

Research Areas:  

Cancer

Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction .
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-19741
CAS No.: 1430844-80-6
Target:  

Bcl-2 Family

Research Areas:  

Cancer

A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.
loading...
    loading...
56
56 Cited Publications
Cat. No.: HY-13328
CAS No.: 1224844-38-5
Purity:  99.63%
Synonyms: INK-128; MLN0128; TAK-228
Target:  

mTOR Autophagy

Research Areas:  

Cancer

Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-10159
CAS No.: 641571-10-0
Purity:  99.94%
Synonyms: AMN107
Target:  

Bcr-Abl Autophagy

Research Areas:  

Cancer

Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
loading...
    loading...
44
44 Cited Publications
Cat. No.: HY-13011
CAS No.: 1256580-46-7
Purity:  99.78%
Synonyms: CH5424802; RO5424802; RG7853
Alectinib (CH5424802; RO5424802; RG7853) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .
loading...
    loading...
44
44 Cited Publications
Cat. No.: HY-13011A
CAS No.: 1256589-74-8
Purity:  99.92%
Synonyms: CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride
Alectinib (CH5424802; RO5424802; RG7853) Hydrochloride is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .
loading...
    loading...
43
43 Cited Publications
Cat. No.: HY-50696
CAS No.: 548472-68-0
Research Areas:  

Cancer

Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.
loading...
    loading...
39
39 Cited Publications
Cat. No.: HY-18708
CAS No.: 1346242-81-6
Synonyms: JNJ-42756493
Target:  

FGFR Apoptosis

Research Areas:  

Cancer

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-12067
CAS No.: 841290-81-1
Purity:  96.70%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
37
37 Cited Publications
Cat. No.: HY-11108
CAS No.: 841290-80-0
Purity:  99.80%
Target:  

Syk FLT3 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM) .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-136927
CAS No.: 129425-81-6
Purity:  99.81%
Target:  

STING

Research Areas:  

Inflammation/Immunology Cancer

MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-18300
CAS No.: 1206161-97-8
Synonyms: GLPG0634
Target:  

JAK HIV

Research Areas:  

Cancer

Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-18300A
CAS No.: 1802998-75-9
Synonyms: GLPG0634 maleate
Target:  

JAK HIV

Research Areas:  

Inflammation/Immunology

Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values ​​of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-32721
CAS No.: 698387-09-6
Synonyms: HKI-272
Target:  

EGFR

Research Areas:  

Cancer

Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively .
loading...
    loading...